FDA Risk “Concept Papers” Expected In March; April Workshop Set
Executive Summary
FDA hopes to release three "concept papers" on risk assessment and risk management March 10 as the first step in developing risk guidances mandated under the Prescription Drug User Fee Act reauthorization
You may also be interested in...
PhRMA Wants Clearer Definition Of Safety “Signal”; FDA Proposes Newsletter
FDA's upcoming pharmacovigilance guidance should include a clearer definition of what constitutes a drug risk "signal," the Pharmaceutical Research & Manufacturers of America maintains
PhRMA Wants Clearer Definition Of Safety “Signal”; FDA Proposes Newsletter
FDA's upcoming pharmacovigilance guidance should include a clearer definition of what constitutes a drug risk "signal," the Pharmaceutical Research & Manufacturers of America maintains
Rx Name Risk Assessments Should Be Conducted By Manufacturers, FDA Says
Drug and biologic sponsors should conduct a risk assessment on the product's name, labeling and packaging to minimize medication errors, an FDA concept paper states